Minerva Neurosciences Inc (NERV)

1.350
-0.060(-4.26%)
After Hours
1.380
+0.030(+2.222%)
- Real-time Data
  • Volume:
    263,903
  • Bid/Ask:
    1.370/1.390
  • Day's Range:
    1.350 - 1.450

NERV Overview

Prev. Close
1.41
Day's Range
1.35-1.45
Revenue
-
Open
1.45
52 wk Range
1.35-4.1
EPS
-0.82
Volume
263,903
Market Cap
57.67M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
647,514
P/E Ratio
-
Beta
0.97
1-Year Change
-59.34%
Shares Outstanding
42,721,566
Next Earnings Date
08 Nov 2021
What is your sentiment on Minerva Neurosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Minerva Neurosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Minerva Neurosciences Inc Company Profile

Minerva Neurosciences Inc Company Profile

Employees
11

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.